Spruce Biosciences, Inc. (SPRB), Monday announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the company's tralesinidase alfa enzyme replacement therapy or TA-ERT for the treatment of Sanfilippo Syndrome Type B, an ultra-rare, serious, and fatal genetic disease.
The designation is backed by the integrated group-level clinical data, demonstrating a rapid, profound, and durable effect of TA-ERT in normalizing Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End, as well as stabilizing cortical grey matter volume and cognitive function in children.
The company plans to submit the Biologics License Application of TA-ERT in the first quarter of 2026.
In the pre-market hours, SPRB is soaring 135.4 percent, to $20.83 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.